Fabry Disease Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

The Fabry Disease market was valued at approximately USD 1,700 million in 2024 and is projected to grow at a significant CAGR during the forecast period (2020–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Fabry disease landscape. By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Fabry disease market is increasingly guided by emerging therapies targeting rare genetic mutations. Enzyme Replacement Therapies (ERTs) represent a highly lucrative therapeutic segment, highlighted by established treatments like FABRAZYME. Currently, FABRAZYME remains a cornerstone of Fabry disease treatment, maintaining significant market presence due to its extensive real-world data and physician familiarity.

DelveInsight's report, "Fabry Disease Treatment Market Insights, Epidemiology, and Market Forecast–2034," provides a comprehensive analysis of the Fabry disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Fabry disease market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, visit Fabry Disease Treatment Market Forecast

Some of the key facts of the Fabry Disease Market Report:

• Key Fabry Disease Companies: Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma, Idorsia Pharmaceuticals, 4D Molecular Therapeutics, AceLink Therapeutics, and others
• Key Fabry Disease Therapies: FABRAZYME (agalsidase beta), REPLAGAL (agalsidase alfa), GALAFOLD (migalastat), ELFABRIO (pegunigalsidase alfa), Venglustat, ST-920 (isaralgagene civaparvovec), Lucerastat, AMT-191, 4D-310, AL01211, EXG110, and others
• The Fabry disease market is expected to surge due to the disease's increasing prevalence awareness and improved diagnostic techniques during the forecast period. Furthermore, launching various late- and mid-stage Fabry disease pipeline products, particularly gene therapies, will significantly revolutionize the Fabry disease market dynamics.

Fabry Disease Overview

Fabry disease is a rare, inherited X-linked lysosomal storage disorder that affects the body's ability to break down certain fatty substances due to a deficiency of the enzyme alpha-galactosidase A. This genetic mutation leads to the accumulation of globotriaosylceramide (GL-3) in cells throughout the body, causing progressive damage to vital organs, including the heart, kidneys, and nervous system. Symptoms often begin in childhood and can include burning pain in the hands and feet, skin lesions (angiokeratomas), digestive issues, and an inability to sweat properly. As the disease advances, it increases the risk of serious complications such as kidney failure, heart disease, and stroke. While there is no cure, treatments such as ERT and chaperone therapy can help slow disease progression and improve quality of life. Early diagnosis and personalized treatment approaches improve patient outcomes.

Key Trends in Fabry Disease Therapeutics Market:

• Rising Adoption of Enzyme Replacement Therapies: Expanding utilization of ERTs like FABRAZYME and REPLAGAL as foundational treatments for Fabry disease.
• Oral Chaperone Therapy Expansion: Growing uptake of GALAFOLD (migalastat) as a convenient oral alternative for eligible patients with specific GLA mutations.
• Gene Therapy Innovation: Development of one-time administered gene therapies including ST-920 and AMT-191 offering durable treatment options.
• Substrate Reduction Therapy Advancement: Development of novel SRTs like Venglustat and Lucerastat targeting GL-3 accumulation.
• Next-Generation ERTs: Introduction of therapies with extended half-lives and improved pharmacokinetics like ELFABRIO with potential for less frequent dosing.
• Precision Medicine & Biomarker Testing: Enhanced molecular diagnostics and genetic testing enabling early identification of disease-causing mutations.
• Newborn Screening Integration: Increased implementation of newborn screening programs for early diagnosis and timely treatment initiation.

Fabry Disease Epidemiology

The report section on Fabry disease epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on phenotype-specific variants including classic and late-onset presentations. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of Fabry disease and plan targeted interventions, research, and treatment strategies.

Fabry Disease Epidemiology Segmentation:

The Fabry disease market report offers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Fabry Disease Diagnosed Prevalent Cases
• Fabry Disease Gender-specific Diagnosed Prevalent Cases
• Fabry Disease Age-specific Diagnosed Prevalent Cases
• Fabry Disease Phenotype -specific Diagnosed Prevalent Cases

Understand which factors are driving Fabry disease epidemiology trends @ Fabry Disease Epidemiology Forecast

Recent Developments In The Fabry Disease Treatment Landscape:

• In February 2025, UniQure Biopharma announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191. Additionally, the Independent Data Monitoring Committee (IDMC) reviewed safety data from the initial two patients enrolled in the first cohort, identifying no significant safety concerns and recommending proceeding with enrollment in the second cohort.
• In February 2025, Sangamo Therapeutics announced updated data from the Phase I/II STAAR study evaluating isaralgagene civaparvovec (ST-920) for the treatment of Fabry disease at the 21st Annual WORLD Symposium, demonstrating the potential of one-time gene therapy administration.
• In February 2025, Amicus Therapeutics announced oral presentations and posters related to migalastat development programs at the 21st Annual WORLD Symposium 2025, showcasing the latest clinical data for GALAFOLD.
• In January 2025, Sanofi announced that the expected regulatory submission date for Venglustat for Fabry disease is in 2026, with Phase III data expected in the second half of 2025.
• In December 2024, CHIESI Farmaceutici and Protalix BioTherapeutics announced that the EMA had validated the variation submission for pegunigalsidase alfa (ELFABRIO) to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every 4 weeks in adult patients with Fabry disease.
• In December 2024, Exegenesis Bio received Orphan Drug Designation from the FDA for EXG110, a novel gene therapy for Fabry disease, underscoring the expanding pipeline.
• In October 2024, Amicus Therapeutics announced that it had entered into a license agreement with Teva Pharmaceuticals. This Agreement resolves the patent litigation brought by Amicus in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of GALAFOLD prior to the expiration of the applicable patents. Pursuant to the terms of the agreement, Amicus will grant Teva Pharmaceuticals a license to market its generic version of GALAFOLD in the US at the beginning of January 2037.
• In October 2024, Sangamo Therapeutics announced alignment with the FDA on an accelerated approval pathway for isaralgagene civaparvovec (ST-920) in Fabry disease, with a BLA submission expected in the second half of 2025.
• In October 2024, Chiesi Global Rare Diseases announced the publication of results from the Phase III BRIGHT study of ELFABRIO 2 mg/kg administered every four weeks for 52 weeks in adult patients with Fabry disease who were previously treated with agalsidase alfa or beta administered every two weeks.

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry disease market or expected to get launched during the study period. The analysis covers Fabry disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fabry Disease Therapies and Key Companies

• FABRAZYME (agalsidase beta): Sanofi (Genzyme)
• REPLAGAL (agalsidase alfa): Takeda Pharmaceuticals
• GALAFOLD (migalastat): Amicus Therapeutics
• ELFABRIO (pegunigalsidase alfa): CHIESI Farmaceutici and Protalix Biotherapeutics
• Venglustat: Sanofi (Genzyme)
• Lucerastat: Idorsia Pharmaceuticals
• ST-920 (isaralgagene civaparvovec): Sangamo Therapeutics
• AMT-191: UniQure Biopharma
• 4D-310: 4D Molecular Therapeutics
• AL01211: AceLink Therapeutics
• EXG110: Exegenesis Bio

To know more about Fabry disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment

Fabry Disease Market Drivers

• Increasing prevalence of Fabry disease globally, particularly through newborn screening programs enabling early diagnosis
• Growth of targeted therapies including ERTs, chaperone therapy, and emerging SRTs for phenotype-specific Fabry disease management
• Advancements in molecular diagnostics and genetic testing enabling identification of disease-causing GLA mutations
• Rising healthcare expenditure and government initiatives supporting rare disease care and patient access programs
• Expanding awareness through diagnostic advancements and physician education
• Development of one-time administered gene therapies offering durable treatment options and improved patient quality of life

Fabry Disease Market Barriers

• High cost of targeted therapies limiting patient access in emerging markets
• Complex clinical trial designs and lengthy regulatory approval processes for rare disease therapies
• Limited efficacy of some emerging therapies in meeting primary clinical endpoints
• Reimbursement challenges and variable healthcare access across different regions
• Patient burden from frequent intravenous infusions associated with ERT administration
• Limited awareness and accessibility in developing markets despite increasing prevalence

Scope of the Fabry Disease Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Fabry Disease Companies: Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeutics, UniQure Biopharma, Idorsia Pharmaceuticals, 4D Molecular Therapeutics, AceLink Therapeutics, and others
• Key Fabry Disease Therapies: FABRAZYME (agalsidase beta), REPLAGAL (agalsidase alfa), GALAFOLD (migalastat), ELFABRIO (pegunigalsidase alfa), Venglustat, ST-920 (isaralgagene civaparvovec), Lucerastat, AMT-191, 4D-310, AL01211, EXG110, and others
• Fabry Disease Therapeutic Assessment: Fabry disease current marketed and Fabry disease emerging therapies
• Fabry Disease Market Dynamics: Fabry disease market drivers and Fabry disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Fabry Disease Unmet Needs, KOL's views, Analyst's views, Fabry Disease Market Access and Reimbursement

Discover more about therapies set to grab major Fabry disease market share @ Fabry Disease Treatment Market